The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages
Abstract
Tumor‐associated macrophages (TAM) are M2d‐polarized cells (IL‐10 high, IL‐12 low, ILT3 high, CD86 low) that accumulate in tumor microenvironment. TAM inhibit antitumor T lymphocyte generation and function, contribute to tumor tolerance and are trophic for tumors. In this study, we investigated whether some immunological factors may reverse TAM immunosuppressive properties. Among 32 cytokines, we have identified IFNγ on its ability to switch immunosuppressive TAM into immunostimulatory cells. Upon IFNγ exposure, TAM purified from ovarian cancer ascites recover a M1 phenotype (IL‐10 low, IL‐12 high), express high levels of CD86 and low levels of ILT3, enhance the proliferation of CD4+ T lymphocytes and potentiate the cytotoxic properties of a MelanA‐specific CD8+ T cell clone. IFNγ‐treated TAM also secreted reduced levels of mediators promoting suppressive T cell accumulation (CCL18) and trophic for tumors (VEGF and MMP9). As TAM derive from the local differentiation of peripheral blood monocytes, we investigated whether IFNγ may also affect TAM generation. In the presence of ovarian ascites, IFNγ skewed monocyte differentiation from TAM‐like cells to M1‐polarized immunostimulatory macrophages. Together, these data show that IFNγ overcomes TAM‐induced immunosuppression by preventing TAM generation and functions. These data highlight that IFNγ used locally at the tumor site could potentiate the efficacy of antitumor immunotherapies based on the generation of effector T cells. © 2009 UICC
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Stein, M., Keshav, S., Harris, N., & Gordon, S. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.287 · Cited by 1,960
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748
Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700
Inflammation and necrosis promote tumour growth
Vakkila, J., & Lotze, M. T. (2004) · Nature Reviews Immunology · doi:10.1038/nri1415 · Cited by 690
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
HMGB1 is an endogenous immune adjuvant released by necrotic cells
Rovere‐Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., Dumitriu, I. E., Müller, S., Iannacone, M., Traversari, C., et al. (2004) · EMBO reports · doi:10.1038/sj.embor.7400205 · Cited by 591
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Luo, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27648 · Cited by 552
From Vanilla to 28 Flavors: Multiple Varieties of T Regulatory Cells
Shevach, E. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.003 · Cited by 549
Tregs and rethinking cancer immunotherapy
Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 547
Duluc, D., Delneste, Y., Tan, F., Moles, M.-P., Grimaud, L., Lenoir, J., Preisser, L., Anegon, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 491
Self-citationAllavena, P., Piemonti, L., Longoni, D., Bernasconi, S., Stoppacciaro, A., Ruco, L., & Mantovani, A. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<359::aid-immu359>3.0.co;2-4 · Cited by 486
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K., Gordon, S., & Balkwill, F. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5023 · Cited by 411
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
Street, S. E. A., Trapani, J. A., MacGregor, D., & Smyth, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020063 · Cited by 375
Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317
Mantovani, A., Allavena, P., & Sica, A. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.016 · Cited by 311
Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., & Clay, T. M. (2008) · Blood · doi:10.1182/blood-2008-01-135319 · Cited by 300
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
The Unsolved Enigmas of Leukemia Inhibitory Factor
Metcalf, D. (2003) · STEM CELLS · doi:10.1634/stemcells.21-1-5 · Cited by 244
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential
Barnett, B., Kryczek, I., Cheng, P., Zou, W., & Curiel, T. J. (2005) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2005.00330.x · Cited by 233
An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation
Fong, C. H. Y., Bebien, M., Didierlaurent, A., Nebauer, R., Hussell, T., Broide, D., Karin, M., & Lawrence, T. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080124 · Cited by 197
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9002-6 · Cited by 183
Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment
Boudreau, N., & Myers, C. (2003) · Breast Cancer Research · doi:10.1186/bcr589 · Cited by 165
Gervois, N., Guilloux, Y., Diez, E., & Jotereau, F. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.5.2403 · Cited by 122
Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.
Aharinejad, S., Abraham, D., Paulus, P., ABRI, H., Hofmann, M., Großschmidt, K., Schäfer, R., Stanley, E. R., & Hofbauer, R. (2002) · PubMed · Cited by 121
Reversal of Tumor-Mediated Immunosuppression
Vieweg, J., Su, Z. Z., Dahm, P., & Kusmartsev, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1924 · Cited by 93
Tumor stress, cell death and the ensuing immune response
Ullrich, E., Bonmort, M., Mignot, G., Kroemer, G., & Zitvogel, L. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402266 · Cited by 90
Duyndam, M. C. A., Hilhorst, M. C. G. W., Schlüper, H. M. M., Verheul, H. M. W., van Diest, P. J., Kraal, G., Pinedo, H. M., & Boven, E. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64873-0 · Cited by 84
Colombo, N., Peccatori, F. A., Paganin, C., Bini, S., Brandely, M., Mangioni, C., Mantovani, A., & Allavena, P. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510109 · Cited by 79
Macrophage Infiltration and Angiogenesis in Human Malignancy
Knowles, H. J., Leek, R., & Harris, A. L. (2004) · Novartis Foundation symposium · doi:10.1002/0470856734.ch14 · Cited by 69
Biologic and Immunologic Therapies for Ovarian Cancer
Berek, J. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.517 · Cited by 69
Hoves, S., Krause, S. W., Schütz, C., Halbritter, D., Schölmerich, J., Herfarth, H. H., & Fleck, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2691 · Cited by 66
Ugurel, S., Seiter, S., Rappl, G., Stark, A., Tilgen, W., & Reinhold, U. (1999) · International Journal of Cancer · Cited by 61
Targeting tumour-associated macrophages
Sica, A., Rubino, L., Mancino, A., Larghi, P., Porta, C., Rimoldi, M., Solinas, G., Locati, M., Allavena, P., & Mantovani, A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1219 · Cited by 58
Fukada, K., Korsching, S. I., & Towle, M. F. (1997) · Growth Factors · doi:10.3109/08977199709021526 · Cited by 23
Immunological memory induced by genetically transduced tumor cells
Dar, M. M., Abdel-Wahab, Z., Vervaert, C. E., Darrow, T. L., Barber, J. R., & Seigler, H. F. (1996) · Annals of Surgical Oncology · doi:10.1007/bf02306279 · Cited by 8
Cited by
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Metadata
- Authors
- Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-04-17
- Volume
- 125
- Issue
- 2
- Pages
- 367-373
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2049999948
- Cited by
- 329
- References
- 57
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.